For Some VCs And Execs, Familiarity Breeds More Start-Ups
This article was originally published in Start Up
Executive Summary
As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.
You may also be interested in...
Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.
Biopharma Deal-Making In 2011: A Year Of Transition
Approvals jumped, venture retrenched and dealmakers expanded on 2010’s creativity. Pharma’s thirst for payer-friendly innovation and emerging markets infrastructure pushed M&A valuations skyward, and threw VCs and drugmakers closer together. The year 2011 was also when we said goodbye to Lipitor, hello to the euro crisis, and “see you soon” to biosimilars.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.